Breaking News

Guardant's CEO on the future of cancer detection; pharma's latest hires and departures

    

 

Pharmalot Ed Silverman

STAT+: With milestones on the horizon, Guardant Health CEOs lay out their vision for cancer detection

By Jonathan Wosen

Guardant Health

"It’s really going to be a defining moment for these liquid biopsy tests," Talasaz said of the readout of a pivotal trial of the SHIELD test.

Read More

STAT+: Up and down the ladder: The latest comings and goings

By Ed Silverman

Alex Hogan/STAT

From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry.

Read More

Opinion: It's time for Congress to stop blocking mitochondrial replacement therapy

By Walter G. Johnson and Diana M. Bowman

Odra Noel/Wellcome

The budget bill rider that funds the FDA mistakenly shuts down research on mitochondrial replacement, which could benefit some families.

Read More

Opinion: Access to kidney transplantation is improving for everyone, but more work remains to be done

By Richard N. Formica

PIERRE-PHILIPPE MARCOU/AFP/Getty Images

Changes made in how donated kidneys and other organs are allocated has helped improve access to transplants for all people.

Read More

Friday, April 22, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments